Respiratory Pathogens Nov 9 2018 - Feb 8 2019

Week Beginning	InfA-H1	InfA-H3	2009 H1N1	Inf B	RSV	All Para	EV / Rhino	Meta pneumo	Adeno	All Corona	Bocca	Myco plasma	Chla mydia	Total Pos	POS FLU	Total	ACL %FLU	US %FLU	IL/WI PCR	Sofia EIA
Feb 8	0	11	32	2	51	3	44	25	8	66	3	3	1	249	45	767	5.9	n/a	n/a	18.4
Feb 1	0	7	38	1	80	13	53	22	12	58	4	3	1	292	46	751	6.1	21.6	16.6	19.6
Jan 26	0	2	31	2	76	11	57	17	6	62	5	1	1	271	35	947	3.7	19.2	12.6	
Jan 18	0	3	30	0	95	13	63	13	9	64	7	5	0	302	33	1064	3.1	15.7	13.3	
Jan 11	0	2	20	0	117	12	70	17	10	45	4	6	1	304	22	1026	2.1	12.7	11.6	10.6
DEC 28	0	4	22	1	128	19	87	21	14	41	4	5	0	346	27	812	3.3	12.7	11.8	9.6
DEC 28	0	5	11	3	105	18	92	15	12	35	11	3	1	311	19	783	2.4	13.7	9.0	3.7
DEC 21	0	2	13	0	105	19	72	10	8	21	10	1	0	261	15	766	2.0	15.6	6.9	7.2
DEC 14	0	0	4	0	55	22	54	3	8	6	6	2	0	160	4	891	0.4	11.0	4.1	5.1
DEC 7	0	0	2	0	63	26	58	9	10	8	2	3	2	183	2	785	0.3	3.6	1.8	3.6
Nov 30	0	0	1	0	42	25	71	9	8	9	5	4	1	175	1	641	0.6	4.2	1.9	1.9
NOV 23	0	2	2	0	51	29	83	5	10	4	3	4	0	193	4	566	0.7	2.4	1.6	2.7
NOV 16	1	0	0	0	25	29	92	3	5	1	4	4	0	164	1	457	0.2	1.7	1.5	0.7
NOV 9	0	0	1	0	23	28	78	4	7	5	1	6	2	155	1	458	0.2	1.2	0.9	1.5

Flu PCR
% Rate


ACL RESP. PANEL - POSITIVITY RATE All viruses - 32.5 %
All Corona
Chla mydia
Myco plasma
All Para
Adeno
Meta pneumo
EV / Rhino
RSV
Inf B
InfA-H3
2009 H1N1
InfA-H1
Bocca
500
450
400
350
300
250
200
150
100
50
0
NOV
NOV 16
NOV 23
Nov 30
DEC 7
DEC 14
DEC 21
DEC 28
DEC 28
Jan 11
Jan 18
Jan 26
Feb 1
Feb 8


ACL RESP. PANEL - Flu PCR - 5.9%, Flu EIA - 18.4%
EIA Sofia
Flu PCR
24.0
19.0
14.0
9.0
4.0
-1.0
NOV 9
NOV 16
NOV 23
Nov 30
DEC 7
DEC 14
DEC 21
DEC 28
DEC 28
Jan 11
Jan 18
Jan 26
Feb 1
Feb 8


ACL RESP. PANEL - RSV PCR - 6.6%, RSV EIA - 7.6%
EIA RSV
RSV PCR
25.0
20.0
15.0
10.0
5.0
0.0
NOV 9
NOV 16
NOV 23
Nov 30
DEC 7
DEC 14
DEC 21
DEC 28
DEC 28
Jan 11
Jan 18
Jan 26
Feb 1
Feb 8

Correlation between RPPNL (FLU PCR) and Sofia (FLUAG) - Accuracy 96.1%

In the last two months 1790 samples were tested by both methods most of them negative, 56/111 samples were positive by EIA when confirmed by PCR. 47 negative EIA samples were tested positive by PCR method. *(ACL correlation data is compiled on samples collected within <48 h). Since positive rate is underrepresented and provides correlation on very small fraction of positive samples – interpret clinical sensitivity with caution.*

Dec 1 2018 to Feb 8 2019				
FLUAG (Sofia) vs RPPNL (PCR) correlation				
		RPPNL		
		+	-	Total
FluAG	+	55	13	68
	-	56	1666	1722
			Total	1790
%				
49.5	Clinical Sensitivity			
99.2	Clinical Specificity			
80.9	Positive Predictive Value (PPV)			
96.7	Negative Predictive Value (NPV)			
96.1	Accuracy			

Feb 2, 2019 Positivity rate 21.6% - Flu A – 98% , Flu B – 2%



FluView

CDC

A Weekly Influenza Surveillance Report Prepared by the Influenza Division

Weekly Influenza Activity Estimates Reported by State and Territorial Epidemiologists*

Week Ending Feb 02, 2019 - Week 5



*This map indicates geographic spread and does not measure the severity of influenza activity.

FluView

A Weekly Influenza Surveillance Report Prepared by the Influenza Division

Influenza-Like Illness (ILI) Activity Level Indicator Determined by Data Reported to ILINet

2018-19 Influenza Season Week 5 ending Feb 02, 2019



*This map uses the proportion of outpatient visits to healthcare providers for influenza-like illness to measure the ILI activity level within a state. It does not, however, measure the extent of geographic spread of flu within a state. Therefore, outbreaks occurring in a single city could cause the state to display high activity levels.

*Data collected in ILINet may disproportionately represent certain populations within a state, and therefore may not accurately depict the full picture of influenza activity for the whole state.

*Data displayed in this map are based on data collected in ILINet, whereas the State and Territorial flu activity map are based on reports from state and territorial epidemiologists. The data presented in this map is preliminary and may change as more data is received.

*Differences in the data presented by CDC and state health departments likely represent differing levels of data completeness with data presented by the state likely being the more complete.

*For the data download you can use Activity Level for the number and Activity Level Label for the text description.

The most prevalent target **were VZV and Crypto – total pos. rate 6.4%**



The most prevalent bacterial targets was **Campy, Salmonella and Giardia**



The most prevalent virus target was **Norovirus** type **I / II – 13%** pos. rate



	BV-Bacterial vagionosis	Candida albicans	Candida galbrata	Candida kruzei	T. vaginalis	M. genitalium	M. hominis	U. parvum	TOTAL % POS
% pos	**21.3**	**12.5**	**1.9**	**0.3**	**2.8**	**0.1**	**6.8**	**17.1**	**62.8**



Neuraminidase Inhibitors **Resistance** in samples collected – as of Feb 2, 2019

Per CDC website	Oseltamivir		Peramivir		Zanamivir	
	Virus Samples tested (n)	Resistant Viruses, (%)	Virus Samples tested (n)	Resistant Viruses, (%)	Virus Samples tested (n)	Resistant Viruses, (%)
Influenza A (H1N1)pdm09	481	0.4	481	0.4	481	0
Influenza A (H3N2)	254	0	254	0	254	0
Influenza B	88	0	88	0	88	0

There 0.4 resistance detected.